A study from the Cell Pathology Division, The Children’s Hospital of Philadelphia, Philadelphia, USA shows that “TGF-β induces the expression of the adaptor Ndfip1 to silence IL-4 production during iTreg cell differentiation.” This study was published in the 15 November 2009 issue of the journal “Nature Immunology” [the number 1 journal in Immunology with an I.F of 24.973] by Prof. Oliver PM, Beal and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Metastatic human tumors: Ndfip1 inhibits cellular proliferation, invasion and metastasis by increasing the expression of metastasis suppressor KRIT1/CCM1 via down regulation of its target gene.
Significance: This study suggests, for the first time, that adoptor Ndfip1, by decreasing the expression of its target gene, it may increase the expression of KRIT1/CCM1. Thus, pharmacological formulations encompassing “Ndfip1 activators” may be used to stall metastatic progression.
Undisclosed information: How Ndfip1 increases the expression of KRIT1/CCM1
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Metastatic human tumors: Ndfip1 inhibits cellular proliferation, invasion and metastasis by increasing the expression of metastasis suppressor KRIT1/CCM1 via down regulation of its target gene, 3/May/2015, 23.22, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org